FDA Drug Recalls

Recalls / Class III

Class IIID-0264-2022

Product

Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg), packaged in cartons containing 3 wallets of 28 Tablets each, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United Stated, Manufactured by: Lupin Limited, Pithampur, (M.P.) - 454775, India, 244896, The individual wallet NDC 68180-904-11 and the carton NDC 68180-904-13.

Affected lot / code info
Lot #: L000784 and L000785, Exp. Date May 2022

Why it was recalled

Subpotent Drug

Recalling firm

Firm
Lupin Pharmaceuticals Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
Harborplace Tower, 111 S Calvert St Fl 21st, Baltimore, Maryland 21202-6174

Distribution

Quantity
4113 cartons
Distribution pattern
nationwide within the United States

Timeline

Recall initiated
2021-11-19
FDA classified
2021-12-01
Posted by FDA
2021-12-08
Terminated
2022-11-15
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0264-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.